ContraVir Pharmaceuticals, Inc. (NasdaqCM:CTRV) will look for acquisitions. ContraVir Pharmaceuticals has filed a registration statement with the US Securities and Exchange Commission (SEC) for public offering of class A units consisting of common stock and warrants, class B units consisting of series D convertible preferred stock and warrants, shares of common stock underlying shares of series D convertible preferred stock and shares of common stock underlying warrants, for aggregate gross proceeds of up to $10.2 million. ContraVir Pharmaceuticals intends to use the net proceeds from the offering for general corporate purposes, including working capital. ContraVir Pharmaceuticals may use the net proceeds from the offering to fund possible acquisitions of other companies, products or technologies, though no such acquisitions are currently contemplated.